Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A <scp>real‐world</scp> cohort analysis-Reference-Cited by-同舟云学术

Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real‐world cohort analysis

Published:2024-02-15 Issue:4 Volume:99 Page:780-784
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Kittai Adam S.¹^ORCID,Hang Ying¹,Bhat Seema A.¹,Clark Abi²,Grever Michael¹,Rhodes Joanna M.³,Roberts Melyssa²,Rogers Kerry A.¹,Teschemaker Anna⁴,Munoz‐Sagastibelza Maria²,Woyach Jennifer A.¹^ORCID,Barrientos Jacqueline C.⁵⁶

Affiliation:

1. Division of Hematology The Ohio State University Columbus Ohio USA

2. US Medical Affairs AstraZeneca Pharmaceuticals Gaithersburg Maryland USA

3. Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA

4. Global Evidence Generation AstraZeneca Pharmaceuticals Gaithersburg Maryland USA

5. Zucker School of Medicine at Hofstra/Northwell Lake Success New York USA

6. Mount Sinai Comprehensive Cancer Center Miami Florida USA

Funder

AstraZeneca

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27241

Reference6 articles.

1. Cancer stat facts: leukemia—chronic lymphocytic leukemia (CLL). National Cancer Institute.2022. Accessed September 11 2023https://seer.cancer.gov/statfacts/html/clyl.html

2. Racial and socioeconomic disparities in CLL/SLL: Analysis of SEER data from 2006-2019

3. Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia

4. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia

5. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL